Page last updated: 2024-12-06

ici 200880

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ICI 200880: synthetic peptide inhibitor of human neutrophil elastase; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6917998
MeSH IDM0190110

Synonyms (6)

Synonym
ici-200880
ici 200880
4-n-(4-chlorophenyl)sulfonyl-1-n-[(2r)-3-methyl-1-oxo-1-[(2s)-2-[(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)carbamoyl]pyrrolidin-1-yl]butan-2-yl]benzene-1,4-dicarboxamide
105120-02-3
l-prolinamide, n-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-l-valyl-n-[3,3,3-trifluoro-1-(1-methylethyl)-2-oxopropyl]-, (r)-
ygpyjefiyypeee-lidazejrsa-n

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Subcutaneous administration of either 50 or 100 mumol/kg (twice/day) of ICI 200,880 for 14 or 28 days prevented the time-dependent increase in alveolar diameter produced by a single intratracheal dose of PPE when compound dosing was initiated 24 h after the enzyme."( Biologic characterization of ICI 200,880 and ICI 200,355, novel inhibitors of human neutrophil elastase.
Falcone, RC; Giles, RE; Knee, C; Krell, RD; Reaves, B; Stein, RL; Strimpler, AM; Williams, JC, 1991
)
0.28
" Subcutaneous administration of either 50 or 100 mumol/kg (twice/day) of ICI 200,880 for 14 or 28 days prevented the time-dependent increase in alveolar diameter produced by a single intratracheal dose of PPE when compound dosing was initiated 24 hours following the enzyme."( Biochemistry and pharmacology of ICI 200,880, a synthetic peptide inhibitor of human neutrophil elastase.
Giles, RE; Krell, RD; Stein, RL; Williams, JC, 1991
)
0.28
" At a 30 min prechallenge interval, compound 9, which incorporates this substituent, had an ED50 of approximately 2 nmol/animal and, qualitatively, afforded a very similar dose-response relationship to that found with a peptidic trifluoromethyl ketone inhibitor, ICI 200,355."( Nonpeptidic inhibitors of human leukocyte elastase. 6. Design of a potent, intratracheally active, pyridone-based trifluoromethyl ketone.
Bernstein, PR; Gomes, BC; Kosmider, BJ; Vacek, EP; Williams, JC, 1995
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's10 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]